Necrotising enterocolitis is a disease that affects the digestive tract of premature newborns. It occurs when portions of the intestine undergo necrosis or tissue death. The disease often strikes premature infants weighing less than 3.3 pounds, and can lead to bowel perforation with accompanying sepsis if not promptly treated. Treatment involves antibiotics and surgery to remove portions of dead intestine tissue in severe cases. Risk factors include prematurity, immaturity of the intestinal immune system, and aggressive enteral feeding regimens.
The Global Necrotising Enterocolitis Market is estimated to be valued at USD 7.10 Billion in 2024 and is expected to reach USD 10.41 Billion by 2031, growing at a compound annual growth rate (CAGR) of 5.6% from 2024 to 2031.
Key players operating in the necrotising enterocolitis market are Medtronic, Nestle, Abbot Nutrition, Masimo, and Bayer Healthcare.
Key Takeaways
Key players: Medtronic and Nestle are investing significantly in developing necrotising enterocolitis treatment devices such as feeding tubes and therapeutics to improve treatment outcomes.
Growing demand: Rising premature births globally and increasing survival rates are expected to drive demand for early diagnostic tools and therapeutics for Necrotising Enterocolitis Market over the forecast period.
Technological advancement: Companies are developing novel imaging and molecular diagnostic technologies to enable early detection of necrotising enterocolitis. Techniques like near infrared spectroscopy show promise in improving diagnosis.
Market Trends
Increasing research investment: Government and pharma industry partnerships are funding clinical trials and research to better understand disease pathogenesis and develop tailored therapeutics.
Focus on nutrition: Companies are developing customized premature infant formulas shown to help reduce necrotising enterocolitis risk by supporting gut maturation. Stricter feeding protocols are also being adopted.
Market Opportunities
Emerging markets: Growing awareness and improving access to healthcare in developing nations presents opportunities to introduce low-cost diagnostics and treatments for necrotising enterocolitis.
Alternative therapies: Adoption of adjunct therapies like probiotics, antimicrobial peptides, and stem cells hold promise alongside standard interventions to boost treatment outcomes.
Impact of COVID-19 on Necrotising Enterocolitis Market Growth
The COVID-19 pandemic has adversely impacted the growth of the global necrotising enterocolitis market. During the initial phase of the pandemic, as several countries imposed nationwide lockdowns, the patient pool seeking treatment for necrotising enterocolitis reduced substantially. However, post-lockdowns, many newborns developed severe conditions requiring intense medical interventions. The growing prevalence of neonatal infections attributed to novel coronavirus further aggravated the necrotising enterocolitis cases globally.
The supply chain disruptions attributed to import-export restrictions affected the timely availability of crucial neonatal medical devices and medicines. Several clinical trials exploring novel treatment avenues also faced delays. The shift towards telemedicine and virtual consultations helped providers to continue remote monitoring of high-risk neonates. With strong vaccination drives globally, the market is anticipated to witness accelerated growth post-pandemic on the back of rising focus on strengthening neonatal healthcare infrastructure and services.
Geographical Regions with Highest Necrotising Enterocolitis Market Value
North America currently dominates the global necrotising enterocolitis market in terms of value, given the high incidence of preterm births and well-established healthcare systems in the US and copyright. According to recent estimates, the North American market accounts for over 35% share of the worldwide revenues. Other major value generating regions include Western Europe and Asia Pacific with countries like Japan, China and India emerging as high potential markets.
Fastest Growing Region in the Necrotising Enterocolitis Market
Asia Pacific region is poised to witness the fastest growth in the necrotising enterocolitis market during the forecast period. Factors such as rising neonatal healthcare spending, growing patient awareness, improving access to advanced treatments and rapid expansions in medical tourism will primarily drive the regional market. Furthermore, the increasing collaborations between domestic and international market players are also augmenting service availability. The Asia Pacific market is expected to expand at a CAGR of more than 8% between 2023-2028.
Get more insights on: Necrotising Enterocolitis Market
About Author:
Ravina Pandya, Content Writer, has a strong foothold in the market research industry. She specializes in writing well-researched articles from different industries, including food and beverages, information and technology, healthcare, chemical and materials, etc. (https://www.linkedin.com/in/ravina-pandya-1a3984191)